FDA warns about seizures with MS drug Ampyra
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Monday said people who take the multiple sclerosis drug Ampyra, from Biogen Idec Inc and Acorda Therapeutics Inc, have a higher risk of seizures when starting the treatment.
The FDA also updated the label for Ampyra, which is approved to help MS patients walk, to warn about the need to check kidney function before people start taking it, and every year after that.
(Reporting by Anna Yukhananov; Editing by Maureen Bavdek)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Uruguay becomes first country to legalize marijuana trade
- Pope Francis named Time's Person of the Year
- Thousands of South Africans line up to see Mandela lie in state |
- China bitcoin arbitrage ends as traders work around capital controls
Time magazine named Pope Francis as its Person of the Year, crediting him with shifting the message of the Catholic Church. Slideshow